Elona Kogan - Oct 15, 2025 Form 4 Insider Report for Apimeds Pharmaceuticals US, Inc. (APUS)

Role
Director
Signature
/s/ Nelson Mullins Riley & Scarborough LLP, Attorney-in-Fact
Stock symbol
APUS
Transactions as of
Oct 15, 2025
Transactions value $
$0
Form type
4
Date filed
10/24/2025, 04:35 PM
Previous filing
May 20, 2025
Next filing
Nov 13, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Kogan Elona Director C/O APIMEDS PHARMACEUTICALS US, INC., 100 MATAWAN ROAD, SUITE 325, MATAWAN /s/ Nelson Mullins Riley & Scarborough LLP, Attorney-in-Fact 2025-10-24 0001679971

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APUS Stock Option (right to buy) Award $0 +3K $0.00 3K Oct 15, 2025 Common Stock, par value $0.01 per share 3K $1.92 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares of common stock subject to the option shall vest in quarterly installments beginning October 1, 2025, such that the award shall be fully vested after three years subject to the reporting person's service to the issuer continuing through and on each vesting date. This option is not exercisable until stockholder approval is obtained to approve an amendment to the issuer's incentive plan (the "Plan") to increase the number of shares of common stock available for issuance under the Plan. The shares of common stock subject to the option shall vest in full upon the occurrence of a Change in Control, as defined in the Plan.

Remarks:

Exhibit List: Ex. 24.1 - Power of Attorney